Tyra Biosciences (TYRA) just put a sharper spotlight on its cash burn after reporting a third quarter net loss of US$51.12 million, compared with a loss of US$29.87 million a year earlier.
The earnings release appears to have rattled sentiment in the very short term, with the share price down 5.83% on the day and 17% over the past three months. However, Tyra Biosciences still carries a 38.8% 1 year total shareholder return that points to earlier optimism now being tested.
Scan beyond Tyra Biosciences and compare its recent volatility with a hand-picked group of 30 resilient stocks with low risk scores that aim to keep drawdowns in check when sentiment turns.
Tyra Biosciences is now trading well below recent highs even after a strong 1 year run. Are you looking at remaining upside, or a story that has already played out in the share price?
Most Popular Narrative: 57% Undervalued
On the analyst consensus Narrative on Simply Wall St, Tyra Biosciences screens as materially undervalued, with a fair value of $48.30 against a last close of $21.00. That view leans heavily on expectations for dabogratinib and how far management can stretch the current balance sheet.
Phase 3 planning for dabogratinib at 60 mg in intermediate risk NMIBC, supported by Phase 2 response rates and tolerability data, could create a clearer path toward a chronic oral treatment option that influences the revenue potential of Tyra Biosciences.
See why 1 investors see Tyra Biosciences as 57% undervalued.
Result: Fair Value of $48.30 (UNDERVALUED)
Still, the Tyra Biosciences story depends heavily on dabogratinib clearing late stage hurdles, while litigation around past disclosures adds another layer of uncertainty.
Find out about the key risks to this Tyra Biosciences narrative.
Another View: Tyra Biosciences Through A Simpler Multiple
Analysts on Simply Wall St frame Tyra Biosciences as undervalued on future earnings, yet its P/B of 2.1x is above the US Biotechs average of 1.8x and comfortably below a peer group at 8.1x. That split hints at mixed signals on risk and opportunity. Which crowd do you trust more?
For a closer look at what the current price implies, and how that compares against peers that screen as cheaper or richer on this yardstick, See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
Conflicted by the combination of optimism and new concerns around Tyra Biosciences right now? Consider reviewing the data yourself and carefully weighing the 5 important warning signs.
Looking for more investment ideas beyond Tyra Biosciences?
Tyra Biosciences may be front of mind right now, yet your portfolio will likely benefit if you keep fresh opportunities on your radar using structured stock screens.
Skip the noise and target companies that combine quality with a margin of safety by scanning a curated set of 35 high quality undervalued stocks before the crowd catches on.
Prioritise resilience by focusing on businesses with balance sheets built to handle shocks, starting with a focused list of solid balance sheet and fundamentals (24 results) that filters out weaker profiles.
Stay a step ahead by reviewing a hand picked pool of 20 high quality undiscovered gems that many investors are not paying attention to yet.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com